<SEC-DOCUMENT>0001493152-26-035218.txt : 20260729
<SEC-HEADER>0001493152-26-035218.hdr.sgml : 20260729
<ACCEPTANCE-DATETIME>20260729170000
ACCESSION NUMBER:		0001493152-26-035218
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20260722
FILED AS OF DATE:		20260729
DATE AS OF CHANGE:		20260729

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Teleman Dan Benjamin
		CENTRAL INDEX KEY:			0002122500
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42796
		FILM NUMBER:		261218692

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		12 SHAUL HAMELECH STREET
		CITY:			KIRYAT ONO
		PROVINCE COUNTRY:   	L3
		ZIP:			00000

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nasus Pharma Ltd
		CENTRAL INDEX KEY:			0002029039
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				516022712
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		29 HARAKEVET ST
		CITY:			TEL AVIV - YAFO
		STATE:			L3
		ZIP:			6618003
		BUSINESS PHONE:		972 54-255-3956

	MAIL ADDRESS:	
		STREET 1:		29 HARAKEVET ST
		CITY:			TEL AVIV - YAFO
		STATE:			L3
		ZIP:			6618003
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0609</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2026-07-22</periodOfReport>

    <notSubjectToSection16>1</notSubjectToSection16>

    <issuer>
        <issuerCik>0002029039</issuerCik>
        <issuerName>Nasus Pharma Ltd</issuerName>
        <issuerTradingSymbol>NSRX</issuerTradingSymbol>
        <issuerForeignTradingSymbol></issuerForeignTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0002122500</rptOwnerCik>
            <rptOwnerName>Teleman Dan Benjamin</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerNonUSAddressFlag>true</rptOwnerNonUSAddressFlag>
            <rptOwnerStreet1>P.O. BOX 284</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>TEL-AVIV-YAFO</rptOwnerCity>
            <rptOwnerNonUSStateTerritory></rptOwnerNonUSStateTerritory>
            <rptOwnerCountry>L3</rptOwnerCountry>
            <rptOwnerZipCode>6100201</rptOwnerZipCode>
            <rptOwnerStateDescription>ISRAEL</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Executive Officer</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <remarks>This Exit Form 4 has been filed solely to report that Reporting Person ceased to serve as the Chief Executive Officer of Nasus Pharma Ltd (the &quot;Issuer&quot;) and resigned as Director from the Board of Directors, effective as of July 22, 2026, and is no longer subject to the reporting obligations under Section 16 of the Securities Exchange Act of 1934, as amended, with respect to the Issuer.</remarks>

    <ownerSignature>
        <signatureName>/s/ Dan Benjamin Teleman</signatureName>
        <signatureDate>2026-07-29</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
